Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute for Cancer Research

University of California

Cornell University

University of Central Florida Research Foundation Inc

The Broad Institute, Inc.

Adjuvance Technologies, Inc.

Johns Hopkins University

The General Hospital Corporation

The City University of New York

East Carolina University

Derek Shieh Tan

David Y Gin

Jeffrey R Gardner

Alberto Fernandez-Tejada

Eric K Chea

Philip O Livingston

Jason S Lewis

Lars Nordstroem

Govindaswami Ragupathi

William Walkowicz

NagaVarakishore Pillarsetty

Michelle Adams

Kai Deng

David A Scheinberg

Sivaraman Dandapani

Debopam Chakrabarti

Govind Ragupathi

Naga Vara Kishore Pillarsetty

Corinne N Foley

J Tyler Martin

Jonghan Lee

Thomas J Gardner

Gustavo Moura-Letts

Rahul Edwankar

Xuequan Lu

Julian Alberto Ferreras

Justin Scott Cisar

Jae-Sang Ryu

Luis E N Quadri

Alyssa Verano

Bracken Roberts

William R Bishai

James H McKerrow

Laurence G Rahme

Cheng Ji

Ivo Lorenz

Everett C Pesci

Glennon Valere Bythrow

Shichun Lun

Debarshi Pratihar

Luis Edmundo Nereo Quadri

Lisa Charlotte Standke

James McKerrow

Alberto Fernandez-tejada

James P Coleman

Indrajeet Sharma

Naga Vara Pillarsetty

William E Walkowicz

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g.,infection (e.g., tuberculosis)). (I)

Salicyl-adenosinemonosulfamate analogs and uses thereof

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.

Compositions and methods for adoptive cell therapy for cancer

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

Triterpene saponins, methods of synthesis and uses thereof

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.

Minimal saponin analogues, synthesis and use thereof

The present disclosure provides compounds of Formula (I'), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g.,() orinfections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.

Anti-parasitic compounds and uses thereof

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Triterpene saponin analogues

A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.

Triterpene saponin variants, methods of synthesis and use thereof

The present disclosure provides compounds of Formula (I'), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g.,() orinfections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein. 

Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g.,infection). 

Anthranilyl-adenosinemonosulfamate analogs and uses thereof

Growing community of inventors

New York, NY, United States of America

Derek Shieh Tan